A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs ASP 8062 (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 21 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 May 2018.
- 21 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 May 2018.
- 17 May 2017 Status changed from not yet recruiting to recruiting.